



**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST:     /     /

**SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED**

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER:    ☐ Male    ☐ Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

**SECTION II: PRESCRIBER INFORMATION**

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY**

1. Does the patient have a diagnosis of migraine, with or without aura, based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria?    ☐ Yes    ☐ No
2. Does the patient have a diagnosis of episodic cluster headache based on ICHD-III diagnostic criteria?    ☐ Yes    ☐ No

*(Form continues on the next page.)*



**New Hampshire Medicaid Fee-for-Service Program**  
**Prior Authorization Drug Approval Form**

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST:     /     /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (CONTINUED)**

*For prevention of migraine headaches, please answer questions 3–5.*

3. Has medication overuse headache been ruled out by trial and failure of titrating off acute migraine treatments in the past? ☐ Yes ☐ No
4. On average, how many migraine days per month has the patient had for the past 3 months?
5. Has the patient tried and failed a  $\geq 1$ -month trial of any 1 of the following oral medications **OR** has the patient had a contraindication to any 1 of the following oral medications? ☐ Yes ☐ No
- antidepressants (e.g., amitriptyline, venlafaxine)
  - beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)
  - anti-epileptics (e.g., valproate, topiramate)
  - angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan)
- a. If **yes**, please list treatment failures and provide dates:

*For prevention of cluster headaches, please answer questions 6–7.*

6. Have other ICHD-III headaches been ruled out? ☐ Yes ☐ No
7. Has the patient tried and failed a  $\geq 1$ -month trial of any 2 of the following oral medications **OR** has the patient had a contraindication to any 2 of the following oral medications? ☐ Yes ☐ No
- suboccipital steroid injections
  - lithium
  - verapamil
  - warfarin
  - melatonin
- a. If **yes**, please list treatment failures and provide dates:

*(Form continues on the next page.)*



**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST:     /     /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (CONTINUED)**

*For treatment of migraine headaches, please answer questions 8–10.*

8. On average, how many migraine days per month has the patient had for the past 6 months?

9. Has the patient tried and failed  $\geq 1$  of the following:

☐ Yes    ☐ No

- NSAIDs
- non-opioid analgesics
- acetaminophen
- caffeinated analgesic combination

a. If **yes**, please list the treatment failures and provide dates:

10. Has the patient tried and failed  $\geq 1$  preferred triptan?

☐ Yes    ☐ No

a. If **yes**, please list the treatment failures and provide dates:

**SECTION IV: FOR RENEWALS ONLY**

11. Has the patient demonstrated a significant decrease in the number, frequency, and/or intensity of headaches?

☐ Yes    ☐ No

12. Has the patient had an overall improvement in function with therapy?

☐ Yes    ☐ No

13. Has the patient experienced any unacceptable toxicity?

☐ Yes    ☐ No

Provide any additional information that would help in the decision-making process. **If additional space is needed, please use another page.**

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: \_\_\_\_\_ DATE: \_\_\_\_\_

Phone: 1-866-675-7755

Fax: 1-888-603-7696

**MagellanRx**  
MANAGEMENT<sup>SM</sup>